AEON Biopharma Reports BPD Type 2a Meeting with FDA, Shareholder Approval.
ByAinvest
Wednesday, Jan 21, 2026 4:08 pm ET1min read
AEON--
AEON Biopharma has held a BPD Type 2a Meeting with the FDA and awaits official meeting minutes. Shareholders have approved the November transactions, including PIPE financing and Daewoong note exchange. AEON is a biopharmaceutical company developing ABP-450 as a biosimilar to BOTOX.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet